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A B S T R A C T
It has been long known that the risk of major congenital malformations is increased among children of
mothers with epilepsy. This is mainly due to the teratogenic effects of antiepileptic drugs although other
factors, such as genetically determined individual susceptibility, are likely to contribute. Recent large
scale prospective epilepsy and pregnancy registries have indicated that the rate of major congenital
malformations may be at most two-fold higher than expected with exposure in utero to the presently
most frequently used antiepileptic drugs such as carbamazepine or lamotrigine. Higher rates are
consistently reported with exposure to valproate. The risk of teratogenic effects appears to be dose
dependent and the lowest effective dose should thus be established before pregnancy regardless of
which antiepileptic drug the woman is taking. Major changes such as switches between drugs should be
avoided when pregnancy is established.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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In 1968 Meadow reported oro-facial clefts and other
abnormalities among babies of mothers who received primidone,
phenytoin, or phenobarbital [1]. Over the more than 50 years since
this ﬁrst report of birth defects in children exposed in utero to
antiepileptic drugs (AEDs), subsequent studies have conﬁrmed
higher birth defects rates among children of mothers with epilepsy
[2,3]. Research since the initial report have also demonstrated a
broader picture of developmental toxicity of AEDs, which in
addition to major congenital malformations (MCM) includes
potential adverse effects on intrauterine growth [4], on cognitive
development of the exposed child [5], and on the behavioral
development [6]. The reasons for the increased risks are
multifactorial and may include genetic factors, the maternal
epilepsy and seizures during pregnancy, socio-economic status,
but accumulating data strongly suggest that AEDs are the main
reason for the increased risks [7]. A pooled analysis of data from 26
studies reported an MCM rate of 6.1% in offspring that had been
exposed to AEDs compared to 2.8% in children of untreated women
with epilepsy, and 2.2% in offspring of mothers without epilepsy
[8]. Similar results were reported in a formal meta-analysis of* Corresponding author at: Department of Neurology, Karolinska University
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AEDs had higher prevalence of MCM than controls (odds ratio (OR)
3.26; 95% CI 2.15–4.93), while the risk for MCM in the offspring of
women with untreated epilepsy was not signiﬁcantly higher than
among non-epilepsy controls (OR 1.92; 95% CI 0.92–4.00) [9].
The present review will focus on the risk of MCM in offspring of
women with epilepsy and in particular the role of AEDs and
possible differences between drugs in their potential to cause
MCM. The topic has been covered in previous reviews and
guidelines [2,7], so emphasis in the present article will be on the
more recent publications.
2. Methodological considerations
Studies aiming at assessment of the risk of MCMs in children
exposed to AEDs in utero face many challenges in particular when
the objective is to compare risks associated with different AEDs.
For obvious ethical reasons randomized studies are not possible.
We are restricted to observational studies with the potential
problems of confounding by other risk factors than the AEDs, e.g.
impact of seizures, type of epilepsy and related or unrelated
genetic factors, and socio-economic circumstances. Second,
fortunately the vast majority of pregnancies in the general
population as well as in women with epilepsy result in healthy
offspring without MCMs. As a consequence large numbers are
needed for meaningful analyses where adjustments can be made
for potential confounding factors. Even larger studies are necessaryserved.
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reporting bias is another challenge. It is more likely that adverse
pregnancy outcomes are reported compared with normal out-
comes. It is therefore essential that information on exposure, i.e.
the AED treatment, is obtained, and enrollment achieved, before
outcome of the pregnancy is known. This is best accomplished in
prospective registries where pregnancies are enrolled in early
pregnancy before any information on outcome is available. This is
becoming more and more difﬁcult as prenatal diagnostic tests are
used earlier in pregnancy. Yet another challenge is the question of a
comparison or control group. Some studies are restricted to
internal comparisons between different AEDs, whereas others
compare MCM rates among AED exposed with pregnancy out-
comes in the general population, or in offspring of untreated
women with epilepsy. The identiﬁcation of MCMs depends on the
vigilance of the observer as well as the time window of
observation. It is therefore essential that exposed cases and
unexposed controls are followed in an identical way.
Traditionally, the ﬁrst suspicion of associations between drug
use in pregnancy and occurrence of MCM has come from
spontaneous reporting to manufacturers or regulators, or from
retrospective case reports. These provide signals that need to be
conﬁrmed or refuted in epidemiological studies, with case–control
or a cohort design. In case–control studies, cases with a birth defect
are compared with controls, children without the defect, with
regard to exposure to AEDs. Such studies are particularly useful
when the event of interest is rare, such as a speciﬁc uncommon
birth defect. A problem with many case–control studies is that the
information on AED use is obtained after the pregnancy outcome is
known, with an inherent risk of recall bias, and an over-estimation
of risks. In addition, while providing a measure of the association
between exposure to a speciﬁc AED and birth defects, case–control
studies do not provide information on the frequency of the
malformations in children exposed to the particular treatment or
to comparators.
Cohort studies can be used to evaluate outcome of pregnancies
with a certain drug. Ideally, information on exposure is obtained
and enrollment in prospective cohort studies completed before
outcome is known, thus avoiding recall bias. Some countries, e.g.
in Scandinavia, have National Medical Birth Registers where
information on maternal drug intake is recorded in early
pregnancy and outcome of pregnancy obtained through other
linked national registers. Such Medical Birth Registers have been
used to assess risks for MCM in association with maternal use of
AEDs [4,10]. They have the advantage of being population-based,
and thus representative, and also to provide the outcome in the
general population as control. There are also limitations: they
lack information on the type of epilepsy (the Swedish Medical
Birth Registry in fact does not specify the indication for the
treatment), occurrence of seizures during pregnancy, details
about drug dose, and many other potentially relevant risk factors.
Pregnancies ending in induced abortions (due to detected MCM
or for other reasons) are excluded in some [10], which under-
estimates the risk.
Epilepsy/antiepileptic drug and pregnancy registers were
established in different countries some 15 years ago. These
prospective observational studies have the speciﬁc objective to
assess and compare risks for MCM with maternal use of different
AEDs during pregnancy [11] and have by now each collected
thousands of pregnancies with AED use. These registers are not
population-based, but they contain much more detailed informa-
tion on AED exposure, types of epilepsy, seizure frequency during
pregnancy, and several other risk factors that are not available in
the Scandinavian Medical Birth Registers. Although the basic
principles of the epilepsy and pregnancy registers are similar, they
differ slightly in some regards, e.g. methods for enrollment,exclusions, outcome criteria and time window for assessment of
outcome. Their results are thus not immediately comparable [11].
The North American AED Pregnancy Registry (NAAPR) enrolls
pregnant women from the US and Canada. The UK and Ireland
Epilepsy and Pregnancy Register includes pregnancies from the UK
and Ireland. EURAP is an international registry enrolling pregnant
women from more than 40 countries world-wide. The Australian
Pregnancy Register and the Kerala Registry of Epilepsy and
Pregnancy in India are part of the EURAP collaboration but also
publish independently [11]. These observational studies have
provided much information in recent years that has had a direct
impact on clinical practice, and the results will be summarized in
the present review.
A different type of antiepileptic drugs and pregnancy registers
are those organized by a pharmaceutical company, where the
GlaxoSmithKline International Lamotrigine Register is the most
established example [12]. A major drawback of these registers is
that they only include pregnancies with the companies’ own
product, one speciﬁc antiepileptic drug, without comparators. This
makes it difﬁcult to draw meaningful conclusions since MCM rates,
for reasons discussed above, cannot be compared across registers.
3. Different types of MCMs
Malformations among offspring of women with epilepsy are not
unique but generally follow a pattern similar to what is seen in the
general population with cardiac defects being the most common
followed by facial clefts, and hypospadias, but with some variation
between different AEDs. A pooled analysis of data from 21
prospective studies looked at four different groups of MCMs
(cardiac, neural tube defects, oro-facial clefts, and hypospadias)
associated with monotherapy exposure to the ﬁve most commonly
used AEDs in these studies [2]. Cardiac malformations were the
most frequent of the four MCMs for carbamazepine, lamotrigine,
barbiturates, and phenytoin, whereas neural tube defects were the
most common for valproate. Cardiac malformations appeared
more frequently with barbiturates than with any of the other AEDs,
whereas neural tube defects and hypospadias were more prevalent
with valproate than with the other AEDs.
NAAPR reported a prevalence of oral clefts of 7.3/1000 infants
exposed to lamotrigine monotherapy, a 10-fold increased rate
compared to unexposed infants [13]. The prevalence of oral clefts
among lamotrigine exposed was lower, 2.5/1000, in ﬁve other
registries [13.] A population-based European case–control study
found no evidence for a speciﬁc increased risk of orofacial clefts
versus other malformations due to lamotrigine, but the study was
not designed to assess whether there is a general increased risk of
malformations with lamotrigine [14]. NAAPR has also observed a
10-fold increase in the rate of oro-facial clefts among infants
exposed to topiramate monotherapy compared to unexposed [15].
A multi-database cohort study recently reported a prevalence of
non-syndromic oral clefts 5.4 times higher among children
exposed to topiramate in utero compared to unexposed children
[16].
Case–control studies based on EUROCAT data have investigated
the risks for speciﬁc MCMs with valproate exposure compared
with no use of an AED. Valproate was associated with increased
risks for spina biﬁda OR 12.7 (95% CI 7.7–20.7), atrial septal defect
2.5 (95% CI 1.4–4.4), cleft palate 5.2 (95% CI 2.8–9.9), hypospadias
4.8 (95% CI 2.9–8.1), polydactyly 2.2 (95% CI 1.0–4.5), and
craniosynostosis 6.8 (95% CI 1.8–18.8) [17]. In a similar case–
control study the only speciﬁc malformation associated with
exposure to carbamazepine monotherapy was spina biﬁda, OR 2.6
(95% CI 1.2–5.3) compared with no AED [18]. Although these data
can inform about associations between a particular AED and
speciﬁc malformations, they rarely provide the direct comparison
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generally derived from the pregnancy registries. Reported rates of
the more common MCMs in the different major registries are
summarized by AED in Tables 1a–1e.
4. Overall rates of major congenital malformations
Rates of MCMs with different monotherapy exposures from the
four major epilepsy and pregnancy registries are summarized in
Table 2. Included are also data from the Norwegian and Swedish
Medical Birth Registers and from GSKs International Lamotrigine
Registry [19–24]. As obvious from Table 2, MCM rates associated
with any speciﬁc AED vary across the different registers, which can
be explained by the methodological differences discussed above.
However, some consistent patterns are seen within each register.
First, with few exceptions the MCM prevalence is highest in
association with valproate exposure in all registers, ranging from
4.7% to 13.8%. MCM rates with the two most frequently used AEDs,
carbamazepine and lamotrigine, are lower than with valproate in
all registers, and comparable between themselves in most studies.
The MCM rate with phenobarbital is reported in three registers,Table 1a
Prevalence, n (%), of more common speciﬁc major congenital malformations among in
Source Cardiovascular Orofacial clefts 
EURAP [19] 8 (0.63) 2 (0.16) 
NAAPR [20] 3 (0.19) 7 (0.45) 
UK Ireland [2123] 9 (0.4) 2 (0.1) 
GSK International [12] 11 (0.61) 2 (0.11) 
* NAAPR only included male offspring as denominator.
Table 1b
Prevalence, n (%), of more common speciﬁc major congenital malformations among in
Source Cardiovascular Orofacial clefts 
EURAP [19] 22 (1.57) 2 (0.14) 
NAAPR [20] 3 (0.29) 5 (0.48) 
UK Ireland [2123] 14 (0.8) 4 (0.2) 
* NAAPR only included male offspring as denominator.
Table 1c
Prevalence, n (%), of more common speciﬁc major congenital malformations among in
Source Cardiovascular Orofacial clefts 
EURAP [19] 22 (2.18) 4 (0.40) 
NAAPR [20] 8 (2.5) 4 (1.2) 
UK Ireland [2123] 14 (1.1) 13 (1.1) 
* NAAPR only included male offspring as denominator.
Table 1d
Prevalence, n (%), of more common speciﬁc major congenital malformations among in
Source Cardiovascular Orofacial clefts 
EURAP [19] 6 (2.76) 1 (0.46) 
NAAPR [20] 5 (2.5) 4 (2.0) 
* NAAPR only included male offspring as denominator.
Table 1e
Prevalence, n (%), of more common speciﬁc major congenital malformations among in
Source Cardiovascular Orofacial clefts 
NAAPR [20] 1 (0.22) 0 
UK Ireland [2123] 0 0 and appears to be in between rates reported for lamotrigine/
carbamazepine and valproate. MCM rates with phenytoin are
highly variable, from 2.4% to 6.7% and based on few exposures in
most registers. The prevalence of MCMs with levetiracetam
appears to be low and so far in a similar range as lamotrigine/
carbamazepine although the number of exposures are still much
lower than for these older AEDs. Exposures to topiramate are too
few to draw ﬁrm conclusions but the data from most registers
indicate a higher prevalence than with lamotrigine/carbamazepine
although in general not as high as with valproate. It should be
emphasized that the precision of the estimates with newer AEDs
such as levetiracetam, oxcarbazepine, and topiramate is still
unsatisfactory due to the limited number of exposed pregnancies.
This is even more the case with other newer generation AEDs such
as gabapentin, pregabalin, zonisamide and lacosimide, which is
why such data are not included here.
Polytherapy with AEDs has traditionally been considered a risk
factor and associated with increased risk of MCM [3,7,8]. However,
this is not a consistent pattern. Analysing data from the Australian
register, and reviewing the literature, Vajda and colleagues
concluded that the fetal hazard of AED polytherapy relative tofants exposed to lamotrigine monotherapy.
Hypospadia* Neural tube defects Others
4 (0.31) 0
0 2 (0.13)
10 (0.5) 2 (0.1)
2 (0.11) 3 (0.17)
fants exposed to carbamazepine monotherapy.
Hypospadia* Neural tube defects Others
9 (0.64) 5 (0.36)
1 (0.19) 3 (0.29)
5 (0.3) 4 (0.2)
fants exposed to valproate monotherapy.
Hypospadia* Neural tube defects Others
17 (1.68) 11 (1.09)
5 (3.1) 4 (1.2)
15 (1.2) 13 (1.1)
fants exposed to phenobarbital monotherapy.
Hypospadia* Neural tube defects Others
1 (0.46) 1 (0.46)
1 (0.97) 0
fants exposed to levetiracetam monotherapy.









Valproate Carbamazepine Lamotrigine Phenobarbital Phenytoin Levetiracetam Oxcarbazepine Topiramate
EURAP [19] 9.7% (98/1010 5.6% (79/1402 2.9% (37/1280) 7.4% (16/217) 5.8% (6/103) 1.6% (2/126) 3.3% (6/184) 6.8% (5/73)
NAAPR [20] 1.1% (5/442) 9.3% (30/323) 3.0% (31/1033) 1.9% (31/1562) 5.5% (11/199) 2.9% (12/416) 2.4% (11/450) 2.2% (4/182) 4.2% (15/359)
UKIre
[2123]
6.7% (82/1220) 2.6% (43/1657) 2.3% (49/2098) 3.7% (3/82) 0.7% (2/304) 4.3% (3/70)
AUS [25] 3.3% (5/153 13.8% (35/253) 5.5% (19/346) 4.6% (14/307) 2.4% (1/41) 2.4% (2/84) 5.9% (1/17) 2.4% (1/42)
NMBR [4] 2.9% 2.8% 6.3% (21/333) 2.9% (20/685) 3.4% (28/833) 7.4% (2/27) 1.7% (2/118) 1.8% (1/57) 4.2% (2/48)
SMBR* 2.1% 4.7% (29/619) 2.7% (38/1430) 2.9% (32/1100) 6.7% (8/119) (0/61) 3.7% (1/27) 7.7% (4/52)
GSK [12] 2.2% (35/1558)
* As reported in Ref. [2].
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valproate than the number of drugs [25]. This is supported by
data from NAAPR, where the prevalence of MCM was 9.1% for
lamotrigine combined with valproate, 2.9% for valproate plus any
AED other than valproate, and 1.9% in association with lamotrigine
monotherapy [26]. Likewise, the prevalence of MCM with
carbamazepine plus valproate was 15.4%, compared with 2.5%
for carbamazepine in combination with any other AED, and 2.9%
for carbamazepine in monotherapy [26].
5. Dose-dependency
EURAP reported that in monotherapy the risk of MCM increases
dose-dependently with all four assessed AEDs, carbamazepine,
lamotrigine, valproate, and phenobarbital [19]. The dose-depen-
dency remained when ten covariates were included in the
multivariable analysis. The lowest malformation rates (2.0%;
1.19–3.24) were observed with less than 300 mg/day of lamo-
trigine at the time of conception and with carbamazepine of less
than 400 mg/day (3.4%; 1.11–7.71). The lowest dose category
analyzed for valproate, less than700 mg/day was associated with a
malformation rate of 5.6%.
Dose-dependency of the MCM risk associated with valproate
has been demonstrated in other registers, including the Australian,
UK and Ireland, and NAPPR [20,21,27]. Malformation rates at
different dosages of valproate, carbamazepine and lamotrigine in
EURAP and UK and Ireland registers are summarized in Table 3.
Suggested cut offs for greater risks have however varied somewhat
but the registers deﬁned dose exposure in different ways. While
EURAP used dose at the time of conception [19], other registers
have used the average dose during the ﬁrst trimester. NAAPR
reported a median average valproate daily dose during the ﬁrst
trimester of 1000 mg for pregnancies with MCM and 750 mg forTable 3
Rates of major congenital malformations (95% CI) with monotherapy with valproate, c
Registers.





MCM % (95% 
Valproate <700 431 5.6% (3.60–8
700 < 1500 480 10.4% (7.83–1
1500 99 24.2% (16.19–
Carbamazepine <400 148 3.4% (1.11–7
400 < 1000 1047 5.3% (4.07–6
1000 207 8.7% (5.24–1
Lamotrigine <300 836 2.0% (1.19–3
300 444 4.5% (2.77–6those without [20]. The lowest MCM rates (<5%) with valproate
were seen at doses up to 500 mg/day [20]. However, NAAPR did
not ﬁnd any apparent dose trend for other AEDs. The UK and
Ireland register reported a signiﬁcant dose effect with valproate
and carbamazepine and a non-signiﬁcant trend toward higher
MCM rate with increasing dose of lamotrigine [21]. The mean daily
dose of valproate was signiﬁcantly higher for infants with MCMs
(1031 mg) compared with those without (898 mg). The MCM rate
with the lowest dose category for valproate (up to 600 mg/day)
was 5.0% compared with 1.9% for carbamazepine at doses up to
500 mg/day, and 2.1% for lamotrigine up to 200 mg/day.
These data support the general strategy of aiming at the lowest
effective dose of an AED for women planning pregnancy.
6. Other risk factors
It is obvious that there is an individual susceptibility to the
teratogenic effects of AEDs as pregnancies with similar exposure in
terms of type and dose of AEDs can result in MCMs as well as in
normal outcomes. Genetic factors are likely to contribute. EURAP
included 11 different non-drug related co-variates in a multivari-
able logistic analysis, and parental history of MCM came out as a
signiﬁcant risk factor with an OR of 4.4 (95%CI 2.1–9.2) [19]. Other
registers have analyzed the recurrence risk of MCM in repeat
pregnancies. The Australian register found that women on AEDs
who had given birth to an infant with MCM in their ﬁrst pregnancy,
and who continued on the same AED, had a risk of 35.7% of having a
child with MCM in their next pregnancy, compared with the
expected rate of 3.1% [28]. The recurrence risk was even greater for
women on valproate, 57.2%. The UK pregnancy register combined
minor and major malformations in their analysis, and reported a
16.8% risk of having another child with such congenital mal-






MCM % (95% CI)
.17) <600 476 5.0%(3.4–7.4)
3.50) >600–<1000 426 6.1% (4.2–8.8)
33.89) >1000 297 10.4% (7.4–14.4)
.71) <500 721 1.9% (1.2–3.2)
.89) >500–<1000 739 2.7% (1.8–4.1)
3.39) >1000 170 5.3% (2.7–9.5)
.24) <200 1143 2.1% (1.4–3.1)
.87) >200–<400 665 2.4% (1.5–4.0)
>400 267 3.4% (1.9–6.5)
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Unfortunately, these studies could not assess the recurrence risk if
treatment was changed from ﬁrst to second pregnancy, since most
women remained on the same AED. Nevertheless, these observa-
tions lend further support to the importance of a genetic inﬂuence
on the teratogenic risks associated with AEDs.
7. Conclusions
Our knowledge concerning the risks of MCM in association with
exposure to AEDs has increased substantially thanks to the
epilepsy and pregnancy registers. A major conclusion is that
overall the increase in the risk with the frequently used AEDs
carbamazepine and lamotrigine in monotherapy is not as great as
previously thought. On the other hand valproate appears to be
consistently associated with a greater risk than other AEDs in
monotherapy as well as in part of polytherapy. The patterns of
MCM also vary with the type of AED where a speciﬁc association
between valproate and neural tube defects has been demonstrated.
The risk of teratogenic effects appears to be dose dependent,
which has been most clearly demonstrated for valproate, where
the risk seems to increase at doses above 500 mg/day although
suggested cut-offs vary between registers. These observations
highlight the importance of aiming for the lowest effective dose
before conception.
Knowledge of the teratogenic potential of newer generation
AEDs other than lamotrigine is limited. Data on levetiracetam are
accumulating, and so far suggest MCM rates similar to those seen
with lamotrigine or carbamazepine, whereas signals indicate
higher rates with topiramate.
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